Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Myriad Genetics (MYGN) in Focus: Stock Up 5.6% in Session
Myriad Genetics, Inc. (MYGN - Free Report) was a big mover last session, as the company saw its shares rise around 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company as the stock is now down 35.7% in the past one-month time frame.
None of the estimates for this stock were revised over the past 30 days. The Zacks Consensus Estimate, however, moved lower over the same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this biomedical stock going forward to see if this recent move higher can last.
Myriad Genetics currently carries a Zacks Rank #3 (Hold).
MYRIAD GENETICS Price
MYRIAD GENETICS Price | MYRIAD GENETICS Quote
A better-ranked stock in the same industry is ANI Pharmaceuticals, Inc. (ANIP - Free Report) , sporting a Zacks Rank #1 (Strong Buy).
Is MYGN going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>